Comparison of the dosimetry and cell survival effect of ¹⁷⁷Lu and ¹⁶¹Tb somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastases.

ABSTRACT:

Background

¹⁷⁷Lu-based radiopharmaceuticals (RPs) are the most used for targeted radionuclide therapy (TRT) due to their good response rates. However, the worldwide availability of ¹⁷⁷Lu is limited. ¹⁶¹Tb represents a potential alternative for TRT, as it emits photons for SPECT imaging, β^--particles for therapy, and also releases a significant yield of internal conversion (IE) and Auger electrons (AE). This research aimed to evaluate cell dosimetry with the MIRDcell code considering a realistic localization of three ¹⁶¹Tb- and ¹⁷⁷Lu-somatostatin (SST) analogs in different subcellular regions as reported in the literature, various cell cluster sizes (25-1000 µm of radius) and percentage of labeled cells. Experimental

SUBMITTER: De Nardo L 

PROVIDER: S-EPMC11561253 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature